Edgewise Therapeutics reports Q1 2023 net loss of $22.8M; cash at $328M; advancing EDG-5506 and EDG-7500 trials

Edgewise Therapeutics, Inc.

2023-Q1 EPS reported -$0.36

Net loss of $22.8M ($0.36 per share) vs $19.4M in prior quarter; R&D spend rose to $19.9M.
Cash, cash equivalents and marketable securities of $328M as of March 31, 2023.
Advancing Phase 2 CANYON (BMD) and LYNX (DMD) trials for EDG-5506; interim DMD data expected Q4 2023.
IND-enabling studies for EDG-7500 (HCM) ongoing; Phase 1 start expected in 2H2023.
Plan to add registration-enabling cohort in CANYON in 2H2023; 12-month ARCH data expected Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edgewise Therapeutics, Inc. reported financial results for first quarter of 2023.

Period: first quarter of 2023
Result: reported results

Exact text from the filing

Edgewise Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Edgewise Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001157523-23-000822

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.